-$0.05 EPS Expected for BioLineRx Ltd. (BLRX) This Quarter
Analysts forecast that BioLineRx Ltd. (NASDAQ:BLRX) will post earnings of ($0.05) per share for the current quarter, Zacks reports. Zero analysts have made estimates for BioLineRx’s earnings. BioLineRx reported earnings per share of ($0.08) during the same quarter last year, which suggests a positive year over year growth rate of 37.5%. The business is scheduled to report its next earnings report on Tuesday, November 28th.
On average, analysts expect that BioLineRx will report full year earnings of ($0.24) per share for the current year, with EPS estimates ranging from ($0.24) to ($0.23). For the next fiscal year, analysts anticipate that the business will report earnings of ($0.23) per share, with EPS estimates ranging from ($0.24) to ($0.22). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover BioLineRx.
BioLineRx (NASDAQ:BLRX) last announced its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.05) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.05).
Several research firms have commented on BLRX. ValuEngine upgraded BioLineRx from a “sell” rating to a “hold” rating in a report on Monday, July 17th. Roth Capital assumed coverage on shares of BioLineRx in a report on Thursday, August 3rd. They set a “buy” rating and a $3.00 price objective on the stock. Zacks Investment Research lowered shares of BioLineRx from a “buy” rating to a “sell” rating in a report on Tuesday, June 20th. Maxim Group set a $3.00 target price on shares of BioLineRx and gave the stock a “buy” rating in a research report on Tuesday, August 8th. Finally, HC Wainwright set a $4.00 target price on shares of BioLineRx and gave the stock a “buy” rating in a research report on Saturday, June 3rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $2.83.
Several institutional investors have recently added to or reduced their stakes in the company. Citadel Advisors LLC raised its holdings in shares of BioLineRx by 443.4% in the 1st quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 86,481 shares during the period. Renaissance Technologies LLC purchased a new stake in shares of BioLineRx during the 1st quarter worth about $126,000. KCG Holdings Inc. grew its holdings in shares of BioLineRx by 715.9% during the 1st quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock worth $168,000 after purchasing an additional 153,687 shares during the period. Finally, Sabby Management LLC purchased a new stake in shares of BioLineRx during the 1st quarter worth about $3,018,000. Institutional investors own 32.27% of the company’s stock.
BioLineRx (NASDAQ BLRX) traded down 2.61% during midday trading on Friday, hitting $1.12. 226,195 shares of the stock were exchanged. BioLineRx has a 12-month low of $0.80 and a 12-month high of $1.42. The firm has a 50 day moving average of $1.08 and a 200-day moving average of $0.96. The stock’s market cap is $107.09 million.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.watchlistnews.com/0-05-eps-expected-for-biolinerx-ltd-blrx-this-quarter/1601817.html.
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.